Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010, for Genesis Biopharma, Inc. (formerly Freight Management Corp.). On March 15, 2010, the company consummated a merger and changed its name, transitioning from a freight management concept to a biopharmaceutical company. The company is in the development stage with no revenue-generating operations to date. It is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | YTD Inception to Mar 31, 2010 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(67,680) | $(6,612) | $(142,168) |
| Cash and Equivalents (End of Period) | $311,799 | $1,568 | $311,799 |
| Total Assets | $536,438 | N/A | $536,438 |
| Total Liabilities | $35,198 | N/A | $35,198 |
| Stockholders' Equity | $501,240 | N/A | $501,240 |
| Weighted Avg Shares Outstanding | 113,176,668 | 121,440,000 | N/A |
Operating Expenses: General and administrative expenses were $67,680 for Q1 2010, primarily driven by intellectual property license fees and SEC filing costs.
Cash Flow: Net cash used in operating activities was $55,619. Net cash provided by financing activities was $360,017, largely due to a private placement of common stock.
Material Changes vs. Prior Period
- Corporate Restructuring: The company completed a reverse merger with Genesis Biopharma, Inc. on March 15, 2010, changing its business focus to biopharmaceuticals (Anti-CD55 Antibody Program).
- Capitalization: A 24-for-1 forward stock split was effected. The company raised approximately $365,000 net in a private placement and issued stock valued at $217,408 for intellectual property rights.
- Expense Increase: Operating expenses increased significantly from $6,612 in Q1 2009 to $67,680 in Q1 2010 due to the acquisition of assets and licensing fees.
- Liquidity: Cash balances increased from $8,257 at the end of 2009 to $311,799 at March 31, 2010, following the private placement.
- Management Change: Former officers resigned, and new leadership (Robert Brooke as CEO, Richard McKilligan as CFO) was appointed.
Outlook, Risks, and Management Commentary
Going Concern: The company's independent auditors have raised substantial doubt about its ability to continue as a going concern. The company has incurred recurring losses and negative operating cash flows since inception.
Liquidity Outlook: Management believes current cash resources ($311,799) are sufficient to sustain operations for approximately six months. Additional financing through debt or equity sales will be required to develop products, which may result in shareholder dilution.
Strategic Focus: The company is developing anti-CD55 antibodies for the treatment of metastatic cancers and lethal infectious diseases. It holds an exclusive license from Cancer Research Technology Limited (CRT) and acquired assets from Hamilton Atlantic.
Risks:
- No assurance that the company will generate sustainable revenues or profits.
- Dependence on external funding; failure to secure financing could halt operations.
- Early-stage research implies a long timeline before potential commercialization.
Investor Verification Checklist
- Capital Runway: Verify if the company has secured additional financing beyond the projected six-month runway.
- Intellectual Property Valuation: Review the terms of the license agreement with CRT and the asset purchase from Hamilton Atlantic to understand future royalty obligations and milestone payments.
- Dilution Risk: Monitor upcoming equity issuances required to fund operations, given the current cash burn rate.
- Going Concern Status: Assess the company's ability to meet liabilities as they come due without further capital raises.
- Stock Split Impact: Confirm the retroactive restatement of share counts and per-share data due to the 24-for-1 split.